BlossomHill Therapeutics, Inc.'s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)

Key Points

• BlossomHill Therapeutics’ quiet period expires September 16, potentially allowing IPO underwriters to begin formal research coverage after the company’s $150 million offering.
• Analyst sentiment is broadly positive: five analysts rate BLSM a Buy and one rates it Hold, resulting in a Moderate Buy consensus and an average price target of $32.20.
• BLSM shares recently traded at $22.93, up 4.2%, while insiders acquired 1,573,900 shares worth approximately $25.2 million during the last quarter.

BlossomHill Therapeutics' (NASDAQ:BLSM - Get Free Report) quiet period will end on Wednesday, September 16th. BlossomHill Therapeutics had issued 9,375,000 shares in its public offering on August 7th. The total size of the offering was $150,000,000 based on an initial share price of $16.00. During BlossomHill Therapeutics' quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

Several analysts have weighed in on BLSM shares. Zacks Research raised BlossomHill Therapeutics to a "hold" rating in a research note on Wednesday, September 2nd. HC Wainwright initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set a "buy" rating and a $35.00 price target on the stock. Lifesci Capital started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an "outperform" rating and a $32.00 price objective on the stock. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research note on Saturday, August 15th. Finally, Guggenheim assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued a "buy" rating and a $30.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, BlossomHill Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.20.

BlossomHill Therapeutics Trading Up 4.2%

Shares of NASDAQ:BLSM opened at $22.93 on Wednesday. BlossomHill Therapeutics has a 12 month low of $15.25 and a 12 month high of $23.37.

Insider Activity at BlossomHill Therapeutics

In other news, Director Orbimed Advisors Llc acquired 625,000 shares of the business's stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director directly owned 2,714,279 shares in the company, valued at $43,428,464. This represents a 29.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director John P. Schmid bought 6,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, with a total value of $96,000.00. Following the purchase, the director directly owned 6,000 shares of the company's stock, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.